Results from drug testing suggest a therapeutic potential of dual PI3K/EGFR inhibition as well as a PI3K inhibitor-CDDP combinations for HPV-ve HNSCC patients exhibiting high levels of Cyclin D1 and Ano1. This evidence concerns the gene ANO1 and head and neck squamous cell carcinoma.